



BREAKOUT SESSION DISCUSSION QUESTIONS

To foster conversation, participants will automatically be placed in breakout rooms after brief presentations for small group live discussion.

After the break-out sessions, participants will automatically rejoin the main session for report-outs.

SESSION 1: DIAGNOSIS AND MANAGEMENT OF AFIB USING IMPLANTABLE AND WEARABLE HEALTH DEVICES

Group 1:

Moderator: William J. Hucker, MD, PhD

Group Members: Seemant Chaturvedi, MD; Beth Hoffman, PA-C, MPH; James T. Kurnick, MD; Joseph E. Marine, MD, MBA, FACC

ACC Staff: Alan Shinkar; Amy Dearborn

Discussion Questions:

1. Which patients should be screened for subclinical AFib?
2. How should we screen for subclinical AFib? Should commercial or medical grade devices be used? Should the devices be implantable or wearable?
3. What is the practice for monitoring patients after a typical flutter ablation? AFib ablation?
4. What are some of the challenges you face as far as receiving data from implantable and wearable health devices? What are some potential ways to alleviate some of these challenges?
5. Are there liability concerns over reading wearable monitoring outputs? Are these concerns the same in cardiology vs neurology?



Group 2:

Moderator: Michael T. Spooner, MD, FACC

Group Members: Kristen B. Campbell, PharmD, FACC; Jack Gannett; Janet K. Han, MD, FACC; Mark S. Link, MD, FACC; Kapil Parakh, MD, PhD

ACC Staff: Ashleigh Covington

Discussion Questions:

1. How should implantable and wearable health devices be used in care management after confirmed AFib diagnosis?
2. How do monitoring strategies change if a patient is on anticoagulants?
3. What should clinicians look for when surveying patients who have subclinical AFib or present with atypical symptoms? Is there a role for wearable monitoring in these situations?
4. What are some of the challenges you face as far as analyzing data from implantable and wearable health devices? What are some potential ways to alleviate some of these challenges?
5. How should clinicians be reimbursed for analyzing and over reading monitoring outputs?

Group 3:

Moderator: Thomas A. Dewland, MD, FACC

Group Members: John P. Erwin, III, MD, FACC; Hooman Kamel, MD, MS; Robert Murdock, DO; Mary P. Orencole, ANP, MS

ACC Staff: Lara Gold

Discussion Questions:

1. Which patients should be screened for subclinical AFib?
2. How should we screen for subclinical AFib? Should commercial or medical grade devices be used? Should devices be implantable or wearable?
3. What is the practice for monitoring patients after a typical flutter ablation? AFib ablation?
4. What are some of the challenges you face as far as analyzing data from implantable and wearable health devices? What are some potential ways to alleviate some of these challenges?
5. How should clinicians be reimbursed for analyzing and over reading monitoring outputs?



Group 4:

Moderator: Andrea M. Russo, MD, FACC

Group Members: Richard A. Bernstein, MD, PhD; Sanjeev P. Bhavnani, MD, FACC;
Kristen K. Patton, MD, FACC; Sherry J. Saxonhouse, MD, FACC; Mellanie True Hills, CSP

ACC Staff: Amanda Ladden-Stirling

Discussion Questions:

1. Which patients should be screened for subclinical AFib?
2. How should we screen for subclinical AFib? Should commercial or medical grade devices be used? Should devices be implantable or wearable?
3. What should clinicians look for when surveying patients who have subclinical AFib or present with atypical symptoms? Is there a role for wearable monitoring in these situations?
4. What are some of the challenges you face as far as receiving data from implantable and wearable health devices? What are some potential ways to alleviate some of these challenges?
5. Are there liability concerns over reading wearable monitoring outputs? Are these concerns the same in cardiology vs neurology?



Group 5:

Moderator: Sarah A. Spinler, PharmD, AACC

Group Members: Geoffrey Barnes, MD, MSc, FACC; John Fanikos, MBA, BS; Marco Perez, MD; Deborah M. Siegal, MD, MSc; Natalia A. Trayanova, PhD, MS, FACC

ACC Staff: Sahisna Bhatia

Discussion Questions:

1. How should implantable and wearable health devices be used in care management after confirmed AFib diagnosis?
2. How do monitoring strategies change if a patient is on anticoagulants?
3. What is the practice for monitoring patients after a typical flutter ablation? AFib ablation?
4. What are some of the challenges you face as far as analyzing data from implantable and wearable health devices? What are some potential ways to alleviate some of these challenges?
5. How should clinicians be reimbursed for analyzing and over reading monitoring outputs?



Group 6:

Moderator: Steven R. Messé, MD

Group Members: Nathan P. Clark, PharmD, BCPS; Taya V. Glotzer, MD, FACC; Ty J. Gluckman, MD, FACC; Brian Olshansky, MD, FACC

ACC Staff: Severa Chavez

Discussion Questions:

1. How should implantable and wearable health devices be used in care management after confirmed AFib diagnosis?
2. How do monitoring strategies change if a patient is on anticoagulants?
3. What should clinicians look for when surveying patients who have subclinical AFib or present with atypical symptoms? Is there a role for wearable monitoring in these situations?
4. What are some of the challenges you face as far as receiving data from implantable and wearable health devices? What are some potential ways to alleviate some of these challenges?
5. Are there liability concerns over reading wearable monitoring outputs? Are these concerns the same in cardiology vs neurology?



SESSION 2: DETECTION/CARE OF AFIB IN PATIENTS POST-CRYPTOGENIC STROKE AND MANAGEMENT/TREATMENT OF THOSE WITH SUBCLINICAL AFIB OF SHORTER DURATION OR LOWER BURDEN

Group 1:

Moderator: William J. Hucker, MD, PhD

Group Members: Seemant Chaturvedi, MD; Beth Hoffman, PA-C, MPH; James T. Kurnick, MD;
Mark S. Link, MD, FACC

ACC Staff: Alan Shinkar, Amy Dearborn

Discussion Questions:

1. How should care be coordinated in patients post-cryptogenic stroke who have AFib? How long should they be monitored? Which types of patients should be monitored?
2. What is the difference in treatment procedure in those with non-cryptogenic stroke (without known AFib) compared to those who had cryptogenic stroke?
3. Which patients following stroke should have implantable loop recorders?
4. What factors beyond CHA2DS2-VASc that should be considered for AFib stroke risk?



Group 2:

Moderator: Michael T. Spooner, MD, FACC

Group Members: Kristen B. Campbell, PharmD, FACC; Jack Gannett; Joseph E. Marine, MD, MBA, FACC; Kapil Parakh, MD, PhD; Deborah M. Siegal, MD, MSc

ACC Staff: Ashleigh Covington

Discussion Questions:

1. How should anticoagulation treatment vary by duration of AFib?
2. How long should a patient be monitored after a short-duration episode of untreated AFib?
3. What patient risk factors should be considered in the setting of subclinical AFib?
4. At what point can you stop anticoagulation in patients with subclinical AFib?
5. In what scenarios can anticoagulants be used intermittently after AFib is detected?
6. How should anticoagulants be used after AFib ablation? Typical flutter ablation? Post-operative AFib?



Group 3:

Moderator: Thomas A. Dewland, MD, FACC

Group Members: Sanjeev P. Bhavnani, MD, FACC; Hooman Kamel, MD, MS; Kristen K. Patton, MD, FACC; Sherry J. Saxonhouse, MD, FACC; Mellanie True Hills, CSP

ACC Staff: Amanda Ladden-Stirling

Discussion Questions:

1. How should care be coordinated in patients post-cryptogenic stroke who have AFib? How long should they be monitored? Which types of patients should be monitored?
2. What is the difference in treatment procedure in those with non-cryptogenic stroke (without known AFib) compared to those who had cryptogenic stroke?
3. Which patients following stroke should have implantable loop recorders?
4. What factors beyond CHA2DS2-VASc that should be considered for AFib stroke risk?



Group 4:

Moderator: Andrea M. Russo, MD, FACC

Group Members: Geoffrey Barnes, MD, MSc, FACC; John P. Erwin, III, MD, FACC; John Fanikos, MBA, BS; Robert Murdock, DO; Mary P. Orencole, ANP, MS

ACC Staff: Lara Gold

Discussion Questions:

1. How should anticoagulation treatment vary by duration of AFib?
2. How long should a patient be monitored after a short-duration episode of untreated AFib?
3. What patient risk factors should be considered in the setting of subclinical AFib?
4. At what point can you stop anticoagulation in patients with subclinical AFib?
5. In what scenarios can anticoagulants be used intermittently after AFib is detected?
6. How should anticoagulant use after AFib ablation? Typical flutter ablation? Post-operative AFib?



Group 5:

Moderator: Sarah A. Spinler, PharmD, AACC

Group Members: Nathan P. Clark, PharmD, BCPS; Adam Cuker, MD, MS; Janet K. Han, MD, FACC; Marco Perez, MD; Natalia A. Trayanova, PhD, MS, FACC

ACC Staff: Sahisna Bhatia

Discussion Questions:

1. How should anticoagulation treatment vary by duration of AFib?
2. How long should a patient be monitored after a short-duration episode of untreated AFib?
3. What patient risk factors should be considered in the setting of subclinical AFib?
4. At what point can you stop anticoagulation in patients with subclinical AFib?
5. In what scenarios can anticoagulants be used intermittently after AFib is detected?
6. How should anticoagulant use after AFib ablation? Typical flutter ablation? Post-operative AFib?

**Group 6:**

Moderator: Steven R. Messé, MD

Group Members: Richard A. Bernstein, MD, PhD; Taya V. Glotzer, MD, FACC; Ty J. Gluckman, MD, FACC; Brian Olshansky, MD, FACC

ACC Staff: Severa Chavez

Discussion Questions:

1. How should care be coordinated in patients post-cryptogenic stroke who have AFib? How long should they be monitored? Which types of patients should be monitored?
2. What is the difference in treatment procedure in those with non-cryptogenic stroke (without known AFib) compared to those who had cryptogenic stroke?
3. Which patients following stroke should have implantable loop recorders?
4. What factors beyond CHA2DS2-VASc that should be considered for AFib stroke risk?